Tesamorelin has an FDA-approved HIV lipodystrophy indication, but not for longevity, ordinary weight loss, cognition, bodybuilding, or anti-aging.
A buyer guide to UFC GYM's PWR Clinics announcement, gym-based longevity medicine, and what to verify before buying GLP-1, TRT, peptide, IV, or recovery programs.
A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.
A buyer guide to Neko Health cost, its scan-first preventive model, New York expansion, false positives, and what to ask before booking.
A buyer guide to Human Longevity exam cost, HLI-style diagnostics, genetics, full-body imaging, and the follow-up questions to ask before paying.
A 2026 buyer guide to longevity clinic follow-up plans: who owns abnormal results, what gets retested, what is included, and which red flags matter.
A buyer scorecard for judging longevity clinic outcomes, follow-up plans, repeat testing, physician accountability, and red flags after an assessment.
Retatrutide is promising in obesity trials, but products sold as retatrutide outside trials have triggered liver-toxicity warnings. Here is how clinic buyers can separate legitimate care from grey-market peptide risk.
A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.
A cautious 2026 guide to cognitive decline, longevity clinics, brain-health tests, lifestyle evidence, referral pathways, and red flags.
A buyer's guide to full-body MRI at longevity clinics: what it can detect, what it misses, real cost models, false positives, and safer alternatives.
GLP-1 microdosing longevity clinics in 2026 need scrutiny: see evidence, healthy-lean caveats, product-quality risks, and buyer red flags.
IV nutrient therapy can be clinically useful for selected deficiencies, but anti-aging claims are weaker. Here is how to compare clinics, costs, and safety protocols.
VO2 max is one of the better-supported longevity metrics, but the value depends on testing quality, medical screening, and a plan after the number.
Lepodisiran and muvalaplin are investigational Lp(a)-lowering drugs. For longevity clinics, the real 2026 action is smarter inherited cardiovascular risk screening.
This weekly WLC intelligence digest covers serious clinic standards, AI diagnostics, GLP-1 programs, full-body MRI, biological-age testing, and peptides.
A buyer guide to the AI health coach longevity clinic stack: biomarker dashboards, wearables, clinician review, privacy, export rights, and follow-up thresholds.
A May 2026 intelligence digest on longevity clinic trends: AI diagnostics, GLP-1s, biomarkers, imaging, and which clinic models deserve buyer trust.
A clear 2026 guide to what longevity clinics do, what they cost, which tests matter, red flags to avoid, and how to compare clinics safely.
Spain is becoming one of Europe’s most interesting longevity clinic markets. Here is how Progevita, SHA, RoseBar Ibiza, and other options differ.
A practical checklist for choosing a longevity clinic in 2026: diagnostics, physician oversight, evidence quality, follow-up, pricing, and red flags.
Peptide therapy is the fastest-growing treatment category at longevity clinics. But RFK Jr.'s push to reclassify 12 banned peptides has created confusion. Here's which peptides clinics actually use, what the evidence says, what they cost, and how to choose a clinic.
Joe Rogan underwent plasmapheresis at Ways2Well in Austin, calling it 'changing the oil in your body.' The FDA-approved procedure is gaining traction in longevity clinics. Here's what it is, the evidence, costs, and whether it's right for you.
With FDA peptide reclassification restoring access to 14 key peptides, longevity clinics offering peptide therapy are seeing renewed interest. Here's what to look for in a peptide clinic, which peptides are commonly offered, and how to evaluate quality and safety.
The LA Times maps how Southern California has become a longevity industry hub — where biotech labs, venture capital, AI diagnostics, and concierge medicine are converging around healthspan extension.
A critical analysis of the 'longevity clinic' phenomenon: serious prevention and offerings with limited evidence coexist. The challenge is separating signal from noise.
The Washington Post investigates the longevity medicine boom — from biohacking expos to high-end clinics — finding that commercial fervor has outpaced both scientific evidence and federal regulation.
A comprehensive review of 2025's longevity milestones: AI-driven drug deals, clinic proliferation, biomarker standardization, and the XPRIZE Healthspan competition reaching its final phase.
Longevity.Technology launches Longevity Clinics World, a directory of 350+ pre-validated clinics globally. The move signals an industry maturing from niche to mainstream.
An editorial in Aging by its Editor-in-Chief reviews the rapid rise of longevity clinics worldwide, highlighting both their potential for data-driven innovation and the serious risks of cost, standardization gaps, and scientific disconnect.
Forbes spotlights longevity clinic travel, where diagnostics, biological age testing, and wellness resorts converge into destination medical tourism.